Vaqta Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to expansion of routine immunization schedules, rising incidence of hepatitis a outbreaks, increased global travel activity, government-led vaccination initiatives, improved vaccine manufacturing standards.

The growth in the forecast period can be attributed to increasing focus on universal vaccination coverage, rising investments in public health infrastructure, expansion of adult and elderly immunization programs, growing demand for combination vaccine strategies, increasing adoption in emerging economies. Major trends in the forecast period include increasing emphasis on preventive vaccination programs, rising adoption of travel-related immunization, growing focus on adult immunization coverage, expansion of cold-chain vaccine distribution, enhanced public health awareness campaigns.

The rising incidence of hepatitis A cases is expected to drive the growth of the Vaqta market in the coming years. Hepatitis A is a highly contagious viral infection that affects the liver, caused by the hepatitis A virus (HAV). The increase in hepatitis A cases is attributed to factors such as poor sanitation and hygiene, outbreaks in communities, unvaccinated populations, foodborne outbreaks, and environmental conditions. Vaqta helps prevent the spread of hepatitis A, particularly in high-risk areas. For example, according to the Health Security Agency, a UK-based government agency, hepatitis A virus infections in the UK typically number around 400 cases per year, but cases rose to over 800 in 2024. Therefore, the rising incidence of hepatitis A is driving the growth of the Vaqta market.

The growing healthcare expenditure is also expected to support the growth of the Vaqta market. Healthcare expenditure refers to the total financial resources spent on health services and products over a specific period, usually measured annually. The rise in healthcare expenditure is driven by aging populations, increasing chronic diseases, medical advancements, and expanded access to healthcare. Increased healthcare spending enables broader access to Vaqta by funding vaccination programs and preventive care initiatives. For instance, according to the Office for National Statistics (ONS), a UK-based government agency, total healthcare expenditure increased by 5.6% in nominal terms between 2022 and 2023, compared with a growth of 0.9% in 2022. Therefore, growing healthcare expenditure is driving the Vaqta market.

The increasing prevalence of chronic diseases is also expected to propel the growth of the Vaqta market. Chronic diseases are long-lasting conditions that persist for a year or more, requiring ongoing medical attention and often limiting daily activities. Their prevalence is linked to aging populations, unhealthy lifestyles, and improved detection and diagnosis. Vaqta plays a critical preventive role for individuals with chronic conditions by protecting them from hepatitis A, which is especially important for those with liver-related diseases or compromised immune systems. For example, according to the World Health Organization (WHO), a Switzerland-based intergovernmental organization, chronic diseases cause 41 million deaths annually worldwide, representing 74% of all fatalities. This includes 17.9 million deaths from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2 million from diabetes. Therefore, the increasing prevalence of chronic diseases is driving growth in the Vaqta market.

Major companies operating in the vaqta market are Merck & Co. Inc.

North America was the largest region in the vaqta market in 2025. The regions covered in the vaqta market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the vaqta market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the vaqta market by increasing costs of imported vaccine antigens, adjuvants, glass vials, syringes, and cold-chain logistics equipment. Public health programs and healthcare providers in North America and Europe are most affected due to reliance on imported vaccine components, while Asia-Pacific faces higher costs in large-scale vaccine distribution. These tariffs raise procurement expenses and can strain public immunization budgets. However, they are also encouraging domestic vaccine production, regional fill-finish capacity expansion, and stronger local vaccine supply chains.

The vaqta market research report is one of a series of new reports that provides vaqta market statistics, including vaqta industry global market size, regional shares, competitors with a vaqta market share, detailed vaqta market segments, market trends and opportunities, and any further data you may need to thrive in the vaqta industry. This vaqta market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Vaqta is a vaccine that protects against hepatitis A, a viral infection affecting the liver. It is an inactivated (killed) virus vaccine, containing a virus that cannot cause disease but stimulates the immune system to provide protection against future infections. Vaqta is a safe and effective vaccine that helps reduce the risk of liver disease caused by hepatitis A.

The primary indications for Vaqta are hepatitis A vaccination, travel vaccination, and routine vaccination. Hepatitis A vaccination is a preventive measure that protects individuals from the hepatitis A virus (HAV), a contagious virus that primarily affects the liver. The vaccine is used across various age groups, including children, adults, and the elderly, and is distributed through hospitals, clinics, retail pharmacies, and specialty pharmacies. End users include hospitals, clinics, ambulatory care facilities, and home care settings.

The vaqta market consists of sales of hepatitis A vaccine, combination vaccines, and vaccine adjuvants. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.